Defense Stocks Investors Are Watching as Iran War Risks Lift Homeland Security Demand

Markets are being pulled in opposite directions by the Iran war, tariff noise, bold political promises and a potential Department of Defense push into drug manufacturing. That mix can punish some assets while quietly creating openings elsewhere. If you care about how policy, conflict and inflation feed into real companies, keep reading. This piece unpacks how three U.S. defense and homeland security stocks are exposed to these shocks right now.

The stocks below are just a starting sample, since the full screen surfaced 46 more U.S. defense and homeland security contractors with equally compelling narratives that are not covered here and may sit in very different places on the risk, value and balance sheet spectrum.

To go straight to the source and size up that wider field, head into the U.S. Defense and Homeland Security Contractors screener to identify, filter and analyze the highest conviction ideas that best match your own risk and return preferences.

Emergent BioSolutions (EBS)

Overview: Emergent BioSolutions develops vaccines, antibody therapies and overdose treatments that help governments and health systems prepare for biological and public health threats.

Operations: Emergent BioSolutions generates about $511 million from medical countermeasure products, $209 million from commercial offerings and $50 million from other revenue streams.

Market Cap: $327 million

Emergent BioSolutions fits this defense and homeland security screen through its role in biodefense stockpiles and public health preparedness contracts, which link directly to how governments think about national security beyond missiles and aircraft.

"Sustained and likely growing demand for medical countermeasures from both U.S. and international governments, evidenced by new and recurring multi-year contracts and recent NATO/EU initiatives expanding defense and biosecurity spending, is expected to provide increasingly predictable revenue and support future top-line growth."

What happens to that predictability depends on how one unresolved funding pressure shapes future contract timing and margin expectations.

That contract pressure is exactly why it helps to read the full narrative for Emergent BioSolutions to see how those funding swings, debt and biodefense optionality really intersect.

Rocket Lab (RKLB)

Overview: Rocket Lab provides small and medium-class rocket launches and space systems that support commercial, government and U.S. defense missions in orbit.

Operations: Rocket Lab generates about US$544 million from Space Systems and roughly US$225 million from Launch Services, with both tied closely to orbital missions.

Market Cap: US$30.4 billion

Rocket Lab matters for this defense and homeland security screen because its launch pads and satellite hardware sit directly in the U.S. space infrastructure that military and intelligence customers rely on when budgets tilt toward orbital capabilities.

"Neutron's successful operation should be that turning point. However, Neutron's failure would risk the entire company."

What happens to margins, funding needs and defense contract appeal depends on how one quiet assumption about future launch cadence actually holds up.

That quiet assumption is exactly what full narrative for Rocket Lab unpacks, showing how launch cadence risk, defense demand and capital needs could be accelerating or quietly stalling Rocket Lab's trajectory.

RADA Electronic Industries (RADA)

Overview: RADA Electronic Industries builds radar and defense electronics for air forces, defense contractors and homeland security customers that rely on precise sensing.

Market Cap: $491 million

RADA Electronic Industries provides direct exposure to defense radar spending at a time when homeland security demand and Department of Defense-aligned budgets remain central to this screener. Forecasts indicate stronger earnings growth expectations relative to the wider U.S. market, while recent pressure on profitability leaves much depending on how an unseen influence on margins develops.

That unseen influence could be critical, so tap into the 2 key rewards and 1 important warning sign to see how radar demand and margin pressure might be pulling in opposite directions.

Seeking Fresh Alternatives Before They Fly

Some opportunities move from quiet to crowded fast. Fresh ideas gain momentum, prices start flying and the best entry points get caught by early movers. Scan new angles now and aim to act early.

• Spot smaller high-conviction stories before they trend by running the 20 high quality undiscovered gems while most investors are still focused on the big tickers.
• Focus on stronger balance sheets as weaker businesses start dropping by filtering through the list of solid balance sheet and fundamentals (25 results) while that quality edge still flies under the radar.
• Seek long term income momentum instead of chasing short bursts by scanning the 8 dividend fortresses before many investors concentrate on the same yield plays.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com